GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evolutionary Genomics Inc (OTCPK:FNAM) » Definitions » YoY Rev. per Sh. Growth

Evolutionary Genomics (Evolutionary Genomics) YoY Rev. per Sh. Growth : 0.00% (As of Dec. 2022)


View and export this data going back to 2011. Start your Free Trial

What is Evolutionary Genomics YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Evolutionary Genomics's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2022 was 0.00%.

Evolutionary Genomics's Revenue per Share for the three months ended in Dec. 2022 was $0.00.


Evolutionary Genomics YoY Rev. per Sh. Growth Historical Data

The historical data trend for Evolutionary Genomics's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolutionary Genomics YoY Rev. per Sh. Growth Chart

Evolutionary Genomics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 233.33 5.00 -90.48 -100.00 -

Evolutionary Genomics Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -100.00 - - - -

Evolutionary Genomics YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Evolutionary Genomics's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2022 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2022 )
=(Revenue per Share (A: Dec. 2022 )-Revenue per Share (A: Dec. 2021 ))/ | Revenue per Share (A: Dec. 2021 ) |
=(0-0)/ | 0 |
=N/A %

Evolutionary Genomics's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2022 is calculated as:

YoY Rev. per Sh. Growth (Q: Dec. 2022 )
=(Revenue per Share (Q: Dec. 2022 )-Revenue per Share (Q: Dec. 2021 )) / | Revenue per Share (Q: Dec. 2021 )) |
=(0-0)/ | 0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evolutionary Genomics YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Evolutionary Genomics's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Evolutionary Genomics (Evolutionary Genomics) Business Description

Traded in Other Exchanges
N/A
Address
4220 Morning Star Drive, Castle Rock, CO, USA, 80108
Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.
Executives
Steve B Warnecke director, 10 percent owner, officer: Chairman, CEO C/O TARGETED MEDICAL PHARMA, INC., 2980 BEVERLY GLEN CIRCLE, SUITE 301, LOS ANGELES CA 90077
Virginia P. Orndorff director 4580 AUGUSTA DR., BROOMFIELD CO 80023
Walter Messier officer: Secretary / Treasurer 1586 GOSHAWK DRIVE, LONGMONT CO 80504
Mark Virgil Boggess director 7857 E OAKBROOK CIR, MADISON WI 53717
Sanford Schwartz director, 10 percent owner 5353 MANHATTAN CIRCLE, STE 101, BOULDER CO 80303
Michael Friess director, 10 percent owner, officer: President/CEO 5353 MANHATTAN CIRCLE, STE 101, BOULDER CO 80303
Chloe M Divita director, officer: Secretary/Treasurer/CFO 5353 MANHATTAN CIRCLE, SUITE 101, BOULDER CO 80303

Evolutionary Genomics (Evolutionary Genomics) Headlines

No Headlines